Conference Coverage

AES: Hormonal contraceptives can boost seizures in epileptics


 

AT AES 2015

References

More women on hormonal contraceptives also reported having a decrease in seizures after starting contraception, compared with those starting on a nonhormonal method (9.5% vs. 5.2%, respectively), which calculated to a 85% relative rate increase for decreased seizures. Depot medroxyprogesterone acetate was the only specific hormonal contraceptive that linked with a higher rate of seizure decreases, compared with combined oral pills, a 95% higher rate.

A second analysis of the results by Dr. Herzog and his associates examined the frequencies of seizure outcomes on hormonal and nonhormonal contraceptives stratifying by type of antiepileptic drug women used when starting a particular contraceptive method. This analysis broke down antiepileptic drugs into four types: enzyme inducing (29%), glucuronidated (such as lamotrigine; 27%), nonenzyme inducing (such as levetiracetam; 22%), enzyme inhibiting (valproate; 8%), and a fifth category that included women who were not on any antiepileptic drug (14%).

This analysis showed that the frequency of seizure increases was significantly greater with hormonal contraceptive use, compared with nonhormonal methods, across all five subgroups of antiepileptic drug type. In addition, the frequency of seizure increases with hormonal contraceptives differed significantly, depending on which antiepileptic drug type women used, but these significant differences among the antiepileptic drug types also occurred among women using nonhormonal contraception.

Women receiving a nonenzyme-inducing drug when starting a hormonal contraceptive reported the lowest frequency of seizure increases, a 12% rate. In contrast, women on an enzyme-inhibiting drug, valproate, had the highest rate of increased seizures when starting a hormonal contraceptive, 29%. This calculated out to about a 2.5-fold relative risk increase for having more seizures when starting hormonal contraception while on valproate, compared with women on a nonenzyme-inducing drug, Dr. Herzog reported.

Physicians “need to be on the lookout for the possibility that seizures could increase when women start a hormonal contraceptive,” he concluded.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

RFVTA system offers alternative to myomectomy
MDedge ObGyn
Radiofrequency volumetric thermal ablation for symptomatic uterine fibroids
MDedge ObGyn
ACOG: Think of menses as a vital sign in adolescents
MDedge ObGyn
Patient denies consent to endometriosis treatment
MDedge ObGyn
2015 Update on osteoporosis
MDedge ObGyn
Managing complications at the time of vaginal hysterectomy
MDedge ObGyn
“Where is it safe to practice obstetrics?” is a broader question
MDedge ObGyn
Annual screening mammography beginning at age 40 saves the most lives
MDedge ObGyn
Does the discontinuation of menopausal hormone therapy affect a woman’s cardiovascular risk?
MDedge ObGyn
Treatment options for adenomyosis supported by limited high-quality data
MDedge ObGyn